$CAPR Class Alert: Capricor Therapeutics Investors May Have Rights in Pending Securities Fraud Class Action - Lead Plaintiff Deadline is September 28
Bleichmar Fonti & Auld LLP announced a class action lawsuit against Capricor Therapeutics alleging securities fraud related to the clinical data integrity for its lead asset, Deramiocel. The complaint claims Capricor failed to disclose changes to its statistical analysis plan, which preceded a 64.5% stock decline in July 2026 following the release of FDA briefing documents.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.